BRIEF published on 06/20/2025 at 07:05, 11 months 29 days ago Relief Therapeutics Faces FDA Setback for RLF-TD011 QIDP Designation RLF-TD011 Orphan Drug FDA Response Epidermolysis Bullosa QIDP Designation
PRESS RELEASE published on 06/20/2025 at 07:00, 11 months 29 days ago Relief Therapeutics Receives FDA Response to QIDP Request for RLF-TD011 Relief Therapeutics receives FDA response on QIDP request for RLF-TD011, impacting EB treatment strategy with Orphan Drug and Rare Pediatric Disease designations Relief Therapeutics RLF-TD011 FDA Response Epidermolysis Bullosa QIDP Request
BRIEF published on 06/12/2025 at 11:05, 1 year ago Relief Therapeutics Announces Results of Annual General Meeting Financial Statements Shareholder Approval Annual Meeting Board Elections Compensation Approval
PRESS RELEASE published on 06/12/2025 at 11:00, 1 year ago Relief Therapeutics Announces Results of Annual General Meeting Relief Therapeutics announces results of its Annual General Meeting with shareholders approving all proposals by a large majority. AGM covers key agenda items and re-election of board members and auditors Board Of Directors Annual General Meeting Shareholders Relief Therapeutics AGM Results
BRIEF published on 05/22/2025 at 07:05, 1 year ago Relief Therapeutics Secures FDA Rare Pediatric Disease Designation for RLF-TD011 FDA Relief Therapeutics RLF-TD011 Epidermolysis Bullosa Rare Pediatric Disease
PRESS RELEASE published on 05/22/2025 at 07:00, 1 year ago Relief Therapeutics Receives FDA Rare Pediatric Disease Designation for RLF-TD011 Relief Therapeutics granted FDA Rare Pediatric Disease Designation for RLF-TD011 in treating epidermolysis bullosa, a rare genetic skin disorder. Potent antimicrobial & anti-inflammatory activity shown FDA Relief Therapeutics RLF-TD011 Epidermolysis Bullosa Rare Pediatric Disease Designation
BRIEF published on 05/15/2025 at 07:05, 1 year 1 month ago Relief Therapeutics Announces 2025 AGM Agenda Annual General Meeting Financial Statements Shareholder Voting Board Re-election Compensation Approval
PRESS RELEASE published on 05/15/2025 at 07:00, 1 year 1 month ago Relief Therapeutics Publishes 2025 Annual General Meeting Agenda Relief Therapeutics announces agenda for its 2025 Annual General Meeting featuring key resolutions and re-elections. Meeting scheduled for June 12 in Geneva, Switzerland Shareholders Switzerland Relief Therapeutics Agenda 2025 Annual General Meeting
BRIEF published on 04/10/2025 at 07:05, 1 year 2 months ago Relief Therapeutics Announces 2024 Financial Results and Strategic Progress Biopharmaceutical Relief Therapeutics Rare Diseases 2024 Financial Results Pipeline Progress
PRESS RELEASE published on 04/10/2025 at 07:00, 1 year 2 months ago Relief Therapeutics Reports 2024 Financial Results and Provides Corporate Update Relief Therapeutics reports 2024 financial results and provides a corporate update, emphasizing operational achievements, pipeline momentum, and strengthened financial position Biopharmaceutical Corporate Update Relief Therapeutics Rare Diseases 2024 Financial Results
Published on 06/19/2026 at 04:30, 18 hours 20 minutes ago Uraniumx Discovery Corp. Announces Acquisition of Common Shares of Gold'n Futures Mineral Corp
Published on 06/19/2026 at 01:20, 21 hours 30 minutes ago American Hotel Income Properties REIT LP Reports Voting Results of Annual and Special Meeting
Published on 06/19/2026 at 01:07, 21 hours 43 minutes ago Usha Resources Announces Share Issuance in Payment of Debenture Interest, Adopts Semi-Annual Reporting
Published on 06/19/2026 at 00:00, 22 hours 50 minutes ago Redwood AI Announces Initiation of Chemical Risk Assessment Module
Published on 06/19/2026 at 20:17, 2 hours 33 minutes ago 2CRSi SA: 2CRSi Responds Point-by-Point to the Grizzly Research Report and Reaffirms the Reality of Its Business Operations
Published on 06/19/2026 at 19:01, 3 hours 49 minutes ago Fuller, Smith & Turner PLC: Publication of the Annual Report and Accounts for the 52 weeks ending 28 March 2026 and Notice of 2026 Annual General Meeting
Published on 06/19/2026 at 18:00, 4 hours 50 minutes ago Successful issue of a CHF 100 million green bond
Published on 06/19/2026 at 16:30, 6 hours 20 minutes ago Amrize to Modernize Montreal Area Cement Plant to be Most Advanced in Eastern Canada
Published on 06/19/2026 at 19:33, 3 hours 17 minutes ago Disclosure of transactions in own shares from June 15 to June 19, 2026
Published on 06/19/2026 at 19:23, 3 hours 26 minutes ago Imerys-06-2026-information-share-capital-and-voting-rights-as-of-31-May-2026
Published on 06/18/2026 at 18:00, 1 day 4 hours ago Outstanding shares and voting rights statement at 31 May 2026
Published on 06/18/2026 at 17:45, 1 day 5 hours ago EURAZEO INVESTS IN LAURALU, A PAN-EUROPEAN PROVIDER OF DEPLOYABLE INDUSTRIAL INFRASTRUCTURE
Published on 06/18/2026 at 17:38, 1 day 5 hours ago Statement of transactions in own shares from June 8, 2026 to June 12, 2026
